Results 301 to 310 of about 197,518 (344)

A Large Mass on the Thigh

open access: yes
JEADV Clinical Practice, EarlyView.
Claudine Howard‐James   +5 more
wiley   +1 more source

Paediatric Acute Generalised and Localised Exanthematous Pustulosis: A Systematic Review

open access: yes
JEADV Clinical Practice, EarlyView.
Miranda K. Branyiczky   +6 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Antifungal Drugs

Pediatrics In Review, 1995
Introduction Fungi have been recognized as pathogens for many years. However, the incidence of fungal infections in the pediatric population has increased substantially due to the increased use of broad-spectrum antibiotics, immunosuppressive agents, hyperalimentation products, and central venous catheters in addition to the acquired ...
J T, Cross, S L, Hickerson, T, Yamauchi
openaire   +2 more sources

Antifungal Drug Resistance

Clinical Infectious Diseases, 2003
The increasing incidence of invasive fungal infections is the result of many factors, including an increasing number of patients with severe immunosuppression. Although new drugs have been introduced to combat this problem, the development of resistance to antifungal drugs has become increasingly apparent, especially in patients who require long-term ...
Juergen, Loeffler, David A, Stevens
openaire   +2 more sources

ORAL ANTIFUNGAL DRUG INTERACTIONS

Dermatologic Clinics, 1997
The recent approval of itraconazole and terbafine for the treatment of onychomycosis has launched a new era in the therapeutic management of this previously resistant form of dermatomycoses. These agents represent safe and effective treatments. The clinician should, however, become knowledgeable with the potential drug interactions that are discussed ...
H I, Katz, A K, Gupta
openaire   +2 more sources

Allylamine Antifungal Drugs

1992
The allylammes constitute a recently developed class of synthetic antimycotics characterized functionally by their action as squalene epoxidase inhibitors.1 Figure 6–1 shows the structures of three representative allylamines. Naftifine, the first of these compounds to be discovered, was first synthesized in 1974,2 and its antifungal properties were ...
N S, Ryder, H, Mieth
openaire   +2 more sources

Antifungal drugs

Journal of Current Hematology & Oncology Research, 2023
Fungal infections continue to emerge as an important cause of infectious disease and mortality in humans. Amphotericin B deoxycholate (ABD), was the first antifungal that was discovered, and it was released in 1958, and flucytosine, which was developed later and is effective against Candida and Cryptococcus, was introduced in 1978.
İlknur Akkuş, Birgül Kaçmaz
openaire   +1 more source

Novel antifungal drugs

Current Opinion in Microbiology, 1999
There have been many new developments in antifungal therapy in the past few years. Some antifungal drugs have been reformulated to reduce toxicity (e.g. new lipid formulations of polyenes), and new derivatives of drugs have been developed to enhance potencies.
openaire   +2 more sources

Antifungal Drugs

2012
There are a number of antifungal drugs authorised for use in animals, the majority being members of the polyene or azole classes. Of these, only two are permitted for use in food animals, at least in the European Union, natamycin and enilconazole. Griseofulvin is a cyclohexenone derivative which has been used in companion and food animal medicine ...
H P Rang   +4 more
openaire   +2 more sources

Echinocandin antifungal drugs

The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire   +3 more sources

Home - About - Disclaimer - Privacy